The effect of exercise program intervention on diabetes

The effect of a submaximal alternative exercise program on heart rate variability profile (HRV), selected resting echocardiographic factors and presentation of multivariate predictive clinical regression model in boys with type 1 diabetes

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211031052926N1

Enrollment

Registered

2021-11-13

Start date

2021-09-23

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes. Type 1 diabetes mellitus

Interventions

Intervention 1: Intervention group: The intermittent exercise program includes a combination of strength and sub-maximal aerobic exercise for twelve consecutive weeks with an average of 65% heart rate

Eligibility

Sex/Gender

Male

Age

12 Years to 18 Years

Inclusion criteria

Inclusion criteria: Type 1 diabetic boys in the age range of 12 to 18 years Having Hba1c more than 6% History of at least 2 years of diabetes

Exclusion criteria

Exclusion criteria: Symptoms of diabetic neuropathy, cerebrovascular or ocular diseases, and respiratory failure Taking certain medications other than insulin Taking drugs that affect resting heart rate High blood pressure Have regular exercise during the week

Design outcomes

Primary

Measure	Time frame
Epinephrine hormone (?EP). Timepoint: Baseline and final (12th week). Method of measurement: Blood samples test.;Norepinephrine hormone (NEP). Timepoint: Baseline and final (12th week). Method of measurement: Blood samples test.;Glycated hemoglobin (HbA1c). Timepoint: Baseline and final (12th week). Method of measurement: Blood samples test.;Fasting blood sugar (FBS). Timepoint: Baseline and final (12th week). Method of measurement: Blood samples test.;High-density lipoprotein (HDL) cholesterol. Timepoint: Baseline and final (12th week). Method of measurement: Blood samples test.;Low-density lipoprotein (LDL) cholesterol. Timepoint: Baseline and final (12th week). Method of measurement: Blood samples test.;Triglyceride (TG). Timepoint: Baseline and final (12th week). Method of measurement: Blood samples test.;Total Cholesterol (TC). Timepoint: Baseline and final (12th week). Method of measurement: Blood samples test.;Dimensions of aorta (AO). Timepoint: Baseline and final (12th week). Method of measurement: Echocardiography (M-mode).;Dimensions of left atrium (LA). Timepoint: Baseline and final (12th week). Method of measurement: Echocardiography (M-mode).;Right ventricle lateral wall (RV). Timepoint: Baseline and final (12th week). Method of measurement: Echocardiography (M-mode).;Left ventricular internal dimension during diastole (LVIDd). Timepoint: Baseline and final (12th week). Method of measurement: Echocardiography (M-mode).;Left ventricular internal dimension during systole (LVIDs). Timepoint: Baseline and final (12th week). Method of measurement: Echocardiography (M-mode).;Inter ventricular septum (IVS). Timepoint: Baseline and final (12th week). Method of measurement: Echocardiography (M-mode).;Posterior ventricular wall thickness (PW). Timepoint: Baseline and final (12th week). Method of measurement: Echocardiography (M-mode).;Fractional shortening (FS). Timepoint: Baseline and final (12th week). Method of measurement: Echocardiography (M-mode).;Ventricu	—

Measure

Time frame

Epinephrine hormone (?EP). Timepoint: Baseline and final (12th week). Method of measurement: Blood samples test.;Norepinephrine hormone (NEP). Timepoint: Baseline and final (12th week). Method of measurement: Blood samples test.;Glycated hemoglobin (HbA1c). Timepoint: Baseline and final (12th week). Method of measurement: Blood samples test.;Fasting blood sugar (FBS). Timepoint: Baseline and final (12th week). Method of measurement: Blood samples test.;High-density lipoprotein (HDL) cholesterol. Timepoint: Baseline and final (12th week). Method of measurement: Blood samples test.;Low-density lipoprotein (LDL) cholesterol. Timepoint: Baseline and final (12th week). Method of measurement: Blood samples test.;Triglyceride (TG). Timepoint: Baseline and final (12th week). Method of measurement: Blood samples test.;Total Cholesterol (TC). Timepoint: Baseline and final (12th week). Method of measurement: Blood samples test.;Dimensions of aorta (AO). Timepoint: Baseline and final (12th week). Method of measurement: Echocardiography (M-mode).;Dimensions of left atrium (LA). Timepoint: Baseline and final (12th week). Method of measurement: Echocardiography (M-mode).;Right ventricle lateral wall (RV). Timepoint: Baseline and final (12th week). Method of measurement: Echocardiography (M-mode).;Left ventricular internal dimension during diastole (LVIDd). Timepoint: Baseline and final (12th week). Method of measurement: Echocardiography (M-mode).;Left ventricular internal dimension during systole (LVIDs). Timepoint: Baseline and final (12th week). Method of measurement: Echocardiography (M-mode).;Inter ventricular septum (IVS). Timepoint: Baseline and final (12th week). Method of measurement: Echocardiography (M-mode).;Posterior ventricular wall thickness (PW). Timepoint: Baseline and final (12th week). Method of measurement: Echocardiography (M-mode).;Fractional shortening (FS). Timepoint: Baseline and final (12th week). Method of measurement: Echocardiography (M-mode).;Ventricu

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Saki

Hamedan University of Medical Sciences

hossein.saki1990@yahoo.com+98 81 3349 3468

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026